Printer Friendly

BIOJECT APPOINTS CHIEF OPERATING OFFICER

 BIOJECT APPOINTS CHIEF OPERATING OFFICER
 PORTLAND, Ore., April 24 /PRNewswire/ -- Bioject's (NASDAQ: BJCTF)


President and Chief Executive Officer Carl Wilcox today announced the appointment of Richard Hollis as Bioject's first chief operating officer (COO). Hollis joined Bioject in December 1991 as executive vice president of marketing and sales.
 "As COO, Hollis will oversee Bioject's marketing and sales operations in preparation for our product launches this year," commented Wilcox. "He will also play a vital role in implementing our corporate renewal program designed to increase the company's revenue ramp-up efficiency, and to shorten product marketing and launch cycles. His medical device experience, focusing on drug delivery systems, will benefit the company as it prepares for the expansion necessary to meet the demands created by the national launch of our advanced needle-free injection management system and planned new product marketing programs."
 Hollis' experience in the pharmaceutical and drug delivery industries includes the launch of several highly successful products and devices. For Genentech, Hollis was on the team that planned and launched Activase (t-PA) with first-year sales of the product exceeding $200 million. Hollis managed the successful market development and launch of intravenous pump systems for IMED Corp., a start-up company based in San Diego. During his career with IMED, he was rapidly promoted from sales to general management positions until the company was sold to Warner Lambert for $468 million in 1984.
 Hollis has developed and implemented strategic plans and successful marketing and sales campaigns for both start-up and established medical companies. Prior to joining Bioject, he was a corporate officer at Portland-based Instromedix, a manufacturer of transtelephonic cardiac monitoring devices.
 Bioject Inc. manufactures and markets the Biojector(R), an injection management system that is able to inject medication through the skin without a needle.
 -0- 4/24/92
 /CONTACT: Dan Zenka or Tim Justice of Bioject, 800-888-3881/
 (BJCTF) CO: Bioject Inc. ST: Oregon IN: MTC SU: PER


SC-JH -- SE001 -- 2366 04/24/92 10:45 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 24, 1992
Words:325
Previous Article:DUKE POWER BATTERY USAGE PROGRAM WINS GOVERNOR'S AWARD
Next Article:HOME PORT BANCORP REPORTS FIRST QUARTER PROFITS


Related Articles
BIOJECT CHIEF EXECUTIVE OFFICER COMMENTS ON AGREEMENT STATUS
ELI LILLY & CO. ENTERS INTO COLLABORATION WITH BIOJECT
SHAREHOLDERS APPROVE DOMESTICATION OF BIOJECT TO U.S.; NEEDLE-FREE INJECTION MANAGEMENT SYSTEM IS READIED FOR SALE
BIOJECT COMPLETES MOVE TO UNITED STATES; BIOJECT MEDICAL TECHNOLOGIES INCORPORATES IN OREGON
BIOJECT EXPANDS PRODUCT DISTRIBUTION WITH NATIONAL NETWORK
BIOJECT EXPANDS PRODUCT DISTRIBUTION WITH NATIONAL NETWORK
BIOJECT SIGNS AGREEMENTS WITH VISITING NURSE ASSOCIATIONS OF AMERICA AND WITH FORMER CHAIRMAN
BIOJECT APPOINTS JAMES C. O'SHEA CHAIRMAN AND CEO
Bioject Hires Two Senior Executives.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters